Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping

• DOI: 10.1016/j.diagmicrobio.2019.02.020
• Publication Date: 2019-03-12T12:17:03Z
• Authors: Jia-Horng Kao; Chun-Yen Lin; Wan-Long Chuang; Yao-Yun Cheng; Jui-Yu Hu; Wen-Kai Liang; Peter Friebe; Stuart Palmer; Chin-Shiou Huang
• Keywords: Sanger sequencing; Hepatitis C

Genotyping of the hepatitis C virus (HCV) is crucial for determining the most efficient anti-viral therapy. The clinical sensitivity and specificity of the IntelliPlexTM HCV Genotyping Kit was determined by comparing the assay results of 307 specimens with the results obtained by Sanger sequencing. Out of 202 HCV-positive specimens tested, 8 samples yielded discrepant results between the IntelliPlex HCV Genotyping Kit and Sanger sequencing. For 5 of these discrepant samples, the IntelliPlex HCV Genotyping Kit classified the correct genotype but failed to show the same single or dual infected status as determined by Sanger sequencing. A total of 105 samples which tested negative for HCV by In-Vitro-Diagnostics (IVD)-approved viral load assay tested negative for HCV by the IntelliPlex HCV Genotyping Kit. The IntelliPlex HCV Genotyping Kit has a clinical specificity of 100% and a clinical sensitivity of 96.9% and is suited to be used in clinical laboratories to genotype HCV.